Analysts Set GH Research PLC (NASDAQ:GHRS) Price Target at $30.67

GH Research PLC (NASDAQ:GHRS - Get Free Report) has been given an average recommendation of "Buy" by the six ratings firms that are covering the company, Marketbeat Ratings reports. Six investment analysts have rated the stock with a buy recommendation. The average twelve-month target price among brokerages that have covered the stock in the last year is $30.67.

GHRS has been the subject of a number of research analyst reports. Cantor Fitzgerald initiated coverage on shares of GH Research in a report on Thursday, February 13th. They set an "overweight" rating and a $14.00 price objective for the company. HC Wainwright reaffirmed a "buy" rating and set a $40.00 price target on shares of GH Research in a research note on Monday, January 27th. Stifel Nicolaus increased their price objective on GH Research from $18.00 to $32.00 and gave the company a "buy" rating in a research report on Thursday, February 27th. Canaccord Genuity Group decreased their price objective on GH Research from $31.00 to $28.00 and set a "buy" rating on the stock in a report on Monday, November 18th. Finally, Royal Bank of Canada began coverage on GH Research in a research note on Friday. They issued an "outperform" rating and a $31.00 target price for the company.

GH Research Price Performance

NASDAQ GHRS traded down $0.38 during trading on Friday, reaching $10.82. The company's stock had a trading volume of 384,748 shares, compared to its average volume of 163,793. The firm has a fifty day moving average of $10.87 and a 200 day moving average of $9.17. GH Research has a one year low of $6.00 and a one year high of $20.50. The stock has a market capitalization of $562.94 million, a PE ratio of -13.70 and a beta of 0.94.

Remove Ads

GH Research (NASDAQ:GHRS - Get Free Report) last posted its quarterly earnings data on Thursday, February 27th. The company reported ($0.17) earnings per share for the quarter, topping the consensus estimate of ($0.23) by $0.06. Research analysts expect that GH Research will post -0.8 earnings per share for the current fiscal year.

Hedge Funds Weigh In On GH Research

Several institutional investors and hedge funds have recently bought and sold shares of the stock. BNP Paribas Financial Markets bought a new stake in GH Research in the fourth quarter valued at approximately $44,000. Two Sigma Investments LP purchased a new position in shares of GH Research in the fourth quarter worth $117,000. Millennium Management LLC purchased a new position in shares of GH Research in the fourth quarter worth $145,000. AdvisorShares Investments LLC raised its holdings in GH Research by 15.4% during the 4th quarter. AdvisorShares Investments LLC now owns 36,011 shares of the company's stock valued at $252,000 after buying an additional 4,806 shares during the last quarter. Finally, Northern Trust Corp boosted its position in GH Research by 26.8% during the 4th quarter. Northern Trust Corp now owns 40,834 shares of the company's stock valued at $286,000 after buying an additional 8,641 shares during the period. 56.90% of the stock is currently owned by institutional investors.

About GH Research

GH Research PLC, together with its subsidiary GH Research Ireland Limited, engages in developing various therapies to treat psychiatric and neurological disorders. It is involved in the development of 5-Methoxy-N,N-Dimethyltryptamine (5-MeO-DMT) therapies for the treatment of patients with treatment-resistant depression (TRD).